Neoadjuvant Chemotherapy in Stage III & IV Epithelial Ovarian Carcinoma (EOC)

Journal International Medical Sciences Academy

Volumn 16, Issue 2, 2003, Pages 89-92

  Kumar, Lalit ^a   Janga, Deepa ^a   Berge, Suchitra ^a   Gupta, S ^a   Kumar, S ^a   Bhatla, N ^a   Kochupillai, V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PLATINUM;

ABDOMINAL HYSTERECTOMY; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE ASSOCIATION; HEPATITIS; HUMAN; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVARY CARCINOMA; PREDICTION; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL ANALYSIS; VOMITING;

EID: 0345686509     PISSN: 0971071X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Griffith CT, Parker LM, Fuller AF. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979;6:235-240.
2. Hacker NF. Controversial aspects of cytoreductive surgery in epithelial ovarian cancer. Bailliere's Clin Obstet Gynecol 1989;3:49-57.
3. Chen SS, Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol 1985;20:190-195.
4. Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol 1992;79:168-172.
5. Potter ME, Patridge EE, Hatch KD, et al. Primary surgical therapy of ovarian cancer: How much and when. Gynecol Oncol 1991;40:195-200.
6. Hunter RW, Alexander NDE, Soutter WP. Meta-analysis of surgery in advanced ovarian cancer. Am J Obstet Gynecol 1992;166:504-511.
7. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78:269-274.
8. Nelson BE, Rosenfield AT and Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. Jn Clin Oncol 1993;11:166-72.
9. Meyer JI, Kennedy AW, Ayoub A and Zepp RC. Ovarian carcinoma; value of CT in predicting success of debulking surgery. Am J Roentgen 1995;165:875-878.
10. Lawton FG, Redman CW, Luesley DM, et al. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Cynecol 1989;73:61-65.
11. Chambers JT, Chambers SK, Voynick IM, et al. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 1990;37:327-331.
12. Jocob JH, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-150.
13. Lim JT, Green A. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol 1993;5:198-202.
14. Van der Burg MEL, van lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. NEJM. 1995;332:629-634.
15. Surwit E, Childers I, ATlas I, et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996;6:356-361.
16. Onnis A, Marchetti M, Padovan P, et al. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynecol Oncol 1996;17:393-396.
17. Schwartz PE, Rutherford TJ, Chambers JT et al. Neoadjuvant chemotherapy for advanced ovarian cancer: Long term survival Gyneco Oncol 1999;72:93-99.
18. Huober J, Meyer A, wagner U, and Wallweiner D. Thje role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer res Clin Oncol 2002;128:153-60.
19. Recchia F, De Fillips S, Rossell M, et al. Primary chemotherapy in stage IV ovarian cancer: A prospective phase II study. Eur J Gynecol Oncol 2001;46:287-291.
20. Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for ptients with poor prognosis in International federation of Gynecology and Obstetrics Stage IIIC Ovarian carcinoma. Cancer 2001;92:2585-91.
21. Kayikciog F, Rose MF, Boran N, Caliskan E, & Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovariqan carcinoma. Int J Cancer 2001;11:466-70.
22. Kumar L, Chandy L, Kriplani A, Kumar S, et al. Chemotherapy in epithelial ovarian cancer. Asian J Obstet Gynaecol 1996;1:35-39.
23. Gupta S. A retrospective analysis of patients with epithelial ovarian cancer, treated at IRCH-AIIMS, submitted as part of DM dissertation, AIIMS, New Delhi May 2000.
24. Vergote IB, de Wever I, decloedt J, Tjalma W, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Sem Oncol 2000;27(suppl.7):31-36.
25. Kumar L, Langa D, Kumar S, Shukla NK, Thulkar S, and Singh R. Neoadjuvant chemotherapy followed byt debulking surgery vs upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma. A prospective randomized study. ASCO Proceedings 2003 (in press).
26. Mc Guire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and 'cisplatin compared with paclitaxel and cisplatin in patients with stage III & IV ovarian cancer. NEJM 1996;334:1-6.
27. Piccart MJ, Bertelsen K, James K, et al. Randomized Intergroup Trials of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three year results. JNCI 2000;92:699-708.
28. Nejit JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-92.